GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Cyclically Adjusted Price-to-FCF

Hyundai Bioscience Co (XKRX:048410) Cyclically Adjusted Price-to-FCF : (As of Jun. 08, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hyundai Bioscience Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Hyundai Bioscience Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co Cyclically Adjusted Price-to-FCF Chart

Hyundai Bioscience Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hyundai Bioscience Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hyundai Bioscience Co's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Hyundai Bioscience Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyundai Bioscience Co's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyundai Bioscience Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hyundai Bioscience Co's Cyclically Adjusted Price-to-FCF falls into.



Hyundai Bioscience Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Hyundai Bioscience Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Hyundai Bioscience Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-198.155/118.8477*118.8477
=-198.155

Current CPI (Mar. 2024) = 118.8477.

Hyundai Bioscience Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 2.324 99.353 2.780
201409 14.020 99.608 16.728
201412 -80.446 99.098 -96.478
201503 -74.120 99.720 -88.337
201506 86.410 100.050 102.645
201509 -36.753 100.110 -43.632
201512 15.351 100.220 18.204
201603 -176.346 100.560 -208.416
201606 3.175 100.790 3.744
201609 -149.382 101.460 -174.982
201612 -56.838 101.560 -66.513
201703 -25.245 102.850 -29.172
201706 -64.584 102.610 -74.804
201709 -98.261 103.490 -112.843
201712 32.472 102.990 37.472
201803 -39.903 104.100 -45.556
201806 -8.668 104.130 -9.893
201809 51.521 105.650 57.957
201812 -49.016 104.350 -55.826
201903 -72.297 104.490 -82.231
201906 8.642 104.880 9.793
201909 -60.649 105.200 -68.517
201912 10.866 105.120 12.285
202003 -75.422 105.540 -84.932
202006 64.177 104.870 72.731
202009 -99.922 106.200 -111.822
202012 -379.426 105.765 -426.358
202103 -3.191 107.357 -3.533
202106 130.695 107.579 144.386
202109 -55.155 108.759 -60.271
202112 -161.048 109.676 -174.515
202203 -92.177 111.806 -97.983
202206 -40.972 114.083 -42.683
202209 -184.242 114.831 -190.686
202212 -141.269 115.200 -145.742
202303 -71.130 116.550 -72.533
202306 -13.442 117.140 -13.638
202309 -51.330 119.111 -51.216
202312 -30.395 118.848 -30.395
202403 -198.155 118.848 -198.155

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hyundai Bioscience Co  (XKRX:048410) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Hyundai Bioscience Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyundai Bioscience Co (XKRX:048410) Business Description

Traded in Other Exchanges
N/A
Address
150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines